This is the No.1 reason startups fail in the first two years, according to the founder of Europe's largest pre-seed fund

Concept Ventures, a Europe-focused pre-seed firm founded in 2018, has raised $88 million for its latest fund and says it bases roughly 80% of investment decisions on founder traits and team dynamics. Reece Chowdhry argues that co-founder chemistry and domain obsession are key predictors of early-stage success — citing Eleven Labs, a $3 billion voice-AI company the firm backed, as an example — and stresses that misaligned founder relationships are the primary cause of failures within 18–24 months. The emphasis on founder evaluation over product readiness has implications for allocators and limited partners allocating to early-stage venture strategies focused on human capital and sector expertise.

Analysis

Market structure: More capital and the messaging from pre-seed leaders (Concept’s $88m fund) bias deal flow toward teams with multi-founder chemistry, benefiting pre-seed VCs that screen for founder-fit, legal/HR automation providers (DocuSign, ADP) and collaboration/stack vendors (Atlassian, Zoom). Expect a 10–30% valuation premium for startups that demonstrate co‑founder alignment vs solo founders over the next 12–24 months, concentrating higher-quality supply into later-stage pipelines and reducing churn of IPO-ready firms.

Risk assessment: Tail risks include a rapid re-rating of early-stage valuations (20–50% drawdown) if a high-profile founder split or an AI-specific regulatory clampdown occurs within 6–24 months; operational risk at portfolio level is founder attrition causing binary write-offs. Near-term (days–weeks) effects are sentiment shifts in private markets; medium-term (3–12 months) are valuation compression/expansion; long-term (1–3 years) is improved survival rate if founder-screening practices scale.

Trade implications: Public exposures that capture structural demand (AI infra, collaboration, legaltech, private-secondaries) are preferred: AI infrastructure (NVIDIA), cloud (MSFT/AMZN), collaboration (TEAM, ZM) and alternative-asset managers with private-market secondaries (BX, KKR). Use options to express asymmetric upside (6–12 month call spreads) and reduce direct exposure to small-cap IPO/SPAC baskets (IPOE) where founder-quality is opaque.

Contrarian angles: Consensus underestimates the pricing power of “founder-quality” as a valuation signal — secondary markets may misprice stakes in tightly held, founder-strong startups, creating 12–24 month ARBITRAGE for secondaries buyers (BX, KKR). Conversely, the market may be overpricing public-era consumer collaboration names on headline demand; look for >25% divergence between revenue growth and enterprise value to identify shorts or pair trades.

Key Decisions for Investors

• Consider establishing a 2–4% long position in NVDA (NVIDIA) via a 6‑month call spread (buy ATM, sell +25% OTM) to capture incremental GPU demand from early-stage AI startups; take profits or re-assess if NVDA rallies >35% or if next quarterly data shows <5% QoQ data‑center revenue growth.
• Allocate 1–2% long to TEAM (Atlassian) for 3–9 months to play higher demand for founder/collaboration tooling; target 15–40% upside, stop-loss -12% absolute or on an earnings miss vs consensus.
• Buy 1% position in DOCU (DocuSign) or ADP for 6–12 months to capture increased legal/HR workflow spend on founder agreements and onboarding; reduce by 50% if YoY transaction volume growth falls below 8% in two consecutive quarters.
• Establish a 1–2% alternative/private-exposure via BX (Blackstone) or KKR to capture secondary/early-stage markups as pre-seed capital grows; hold 12–24 months and trim if disclosed NAV markdowns exceed 10% or fundraising momentum stalls.
• Reduce exposure to IPO/SPAC basket ETF IPOE by ~50% over the next 3 months and redeploy into the above names; if EU/US AI regulatory guidance within 60 days imposes fines or disclosure rules exceeding $50M per incident, cut NVDA/AMZN/MSFT exposure by 50% until clarity returns.